A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

  1. Trnĕny, M.
  2. Verhoef, G.
  3. Dyer, M.J.S.
  4. Yehuda, D.B.
  5. Patti, C.
  6. Canales, M.
  7. Lopez, A.
  8. Awan, F.T.
  9. Montgomery, P.G.
  10. Janikova, A.
  11. Barbui, A.M.
  12. Sulek, K.
  13. Terol, M.J.
  14. Radford, J.
  15. Guidetti, A.
  16. Di Nicola, M.
  17. Siraudin, L.
  18. Hatteville, L.
  19. Schwab, S.
  20. Oprea, C.
  21. Gianni, A.M.
Aldizkaria:
Haematologica

ISSN: 1592-8721,  0390-6078

Argitalpen urtea: 2018

Alea: 103

Zenbakia: 8

Orrialdeak: 1351-1358

Mota: Artikulua

DOI: 10.3324/HAEMATOL.2017.168401 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus